TLDR
- Tilray Brands stock surged 31.55% in after-hours trading to $11.09 on Thursday
- Company launched Amped Live Resin Liquid Diamond vape cartridges under Redecan brand
- Live resin vapes grew 6.3% in Canadian market over past six months
- Reports suggest Trump administration may reclassify marijuana from Schedule I to Schedule III
- Stock down 42.26% year-to-date despite recent gains
Tilray Brands Inc. shares jumped more than 30% in after-hours trading Thursday, catching the attention of investors across the cannabis sector. The stock climbed to $11.09 after closing regular trading at $8.43.
The surge came after Tilray announced a new product line under its Redecan Cannabis brand. The company launched Amped Live Resin Liquid Diamond 1g 510 cartridges, marking Redecan’s first entry into the live resin-liquid diamond category.
The debut lineup features two strains: Space Age CK and Blueberry DNTS. Each cartridge combines 80% Legit Live Resin with 20% Liquid Diamonds, designed to deliver full-spectrum cannabinoids and strain-specific terpenes.
The timing appears strategic for Tilray. According to company data, live resin vapes have delivered 6.3% category growth over the past six months in Canada. Liquid Diamond formats remain among the top-selling vape products nationwide.
Vape basket penetration peaks from December to February, which aligns perfectly with this launch timing. The winter months typically see increased consumer demand for these products.
Product Details and Market Position
The Amped cartridges feature a TrueDraw Ceramic core made from medical-grade zirconia ceramic. This biocompatible material offers high strength and durability.
The wide-body design aims to improve airflow and prevent clogs, a common complaint with vape products. Space Age CK offers floral, fruit, and cake notes, while Blueberry DNTS delivers sweet and sour berry flavors.
The cartridges are currently available in Ontario and Alberta. National distribution across Canada is planned for early 2026 through authorized cannabis retailers.
Products are only available to consumers aged 19 and older, following Canadian cannabis regulations. The company positions these as premium offerings in a growing market segment.
Stock Performance and Market Context
The after-hours rally came on the same day The Washington Post reported President Donald Trump may direct federal agencies to reclassify marijuana. The potential move would shift cannabis from Schedule I to Schedule III.
Schedule I drugs like heroin and LSD have no accepted medical use and high abuse potential. Schedule III drugs have recognized medical uses and lower abuse potential.
A White House spokesperson told Forbes no final decisions have been made on marijuana rescheduling. The reports still fueled optimism across cannabis stocks.
Despite Thursday’s gains, Tilray has faced a tough year. The stock is down 42.26% year-to-date but has rebounded 102.64% over the past six months.
Tilray has a market capitalization of $9.49 billion. The 52-week range sits between $3.51 and $23.20.
In premarket trading Friday, shares climbed another 27.52% to $10.75 as of 7:21 AM EST. Trading volume surged as investors processed the news.
Analysts noted the new products improve Tilray’s positioning in higher-margin cannabis formats. However, profitability concerns remain for the company.
The stock closed Thursday’s regular session up 2.06% at $8.43. The after-hours movement represented one of the strongest single-day gains in recent months for Tilray.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
